Study in HFpEF patients to compare the effect of AZD9977 and Spironolactone on Serum Potassium

Exclusion Criteria

• - Patients with documented LVEF <40% at any time (i.e. patients with previously impaired LVEF that has now improved are not permitted).
• - Patients experiencing acute decompensation of heart failure requiring hospital admission or escalation in therapy.
• - Primary cardiomyopathy (e.g. constrictive, restrictive, infiltrative, toxic, hypertrophic, congenital or any primary cardiomyopathy in judgment of Investigator).
• - Hyponatraemia, defined as serum Na+ <135 mmol/L at the time of enrollment.
• - Persistent resting sinus tachycardia >110 bpm or sinus bradycardia <45bpm.
• - Systolic blood pressure (BP) <110mmHg or >180mmHg.
• - Diastolic BP <60 mmHg or >100 mmHg.
• - Patients previously intolerant to MRA (e.g. spironolactone or eplerenone) for any reason.
• - Medical conditions associated with development of hyperkalaemia (e.g. Addison’s disease).
• - Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level ≥2.0 times the upper limit of normal (ULN).
• - Patients who have been taking an MR antagonist within 1 month prior to randomization.